Adhesive proteins and the hematogenous spread of cancer

Acta Haematologica

Volumn 97, Issue 1-2, 1997, Pages 29-39

  Tuszynski, George P ^a   Wang, Thomas N ^a   Berger, David ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Adhesive proteins; Metastasis; Platelets; Receptors; Thrombospondin 1

Indexed keywords

CELL ADHESION MOLECULE; CELL SURFACE RECEPTOR; FIBRONECTIN; FIBRONECTIN RECEPTOR; HERMES ANTIGEN; HYALURONIC ACID; LAMININ; LAMININ RECEPTOR; PROTEOGLYCAN; THROMBOSPONDIN; VITRONECTIN;

CANCER INVASION; CELL ADHESION; EXTRACELLULAR MATRIX; HEMOSTASIS; METASTASIS; PRIORITY JOURNAL; REVIEW; THROMBOCYTE; THROMBOCYTE AGGREGATION; TUMOR CELL;

ANIMALS; ANTIGENS, CD36; ANTIGENS, CD44; BASEMENT MEMBRANE; CELL ADHESION; CELL ADHESION MOLECULES; ENDOTHELIUM, VASCULAR; FIBRONECTINS; HEMOSTASIS; HUMANS; HYALURONIC ACID; INTEGRINS; LAMININ; MEMBRANE GLYCOPROTEINS; MODELS, BIOLOGICAL; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; ORGAN SPECIFICITY; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, LAMININ; RECEPTORS, VITRONECTIN; THROMBOSPONDINS;

EID: 14444274809     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000203657     Document Type: Article

References (96)

1. Recamicr. JCA: L’histoire dc la memc maladic. Gabor. 1829. vol 2. p 110.
2. Paget S: Distribution of secondary growths in cancer of the breast. Lancet 1889:1:571.
3. Billroth T: Lectures on Surgical Pathology and Therapeutics: A I Iandbook for Students and Practitioners. London. The New Syndeham Society. 1878, p 355.
4. Karpatkin S, Pcarlstein E, Ambrogio C. Coller BS: Role of adhesive proteins in platelet tumor interactions in vitro and metastasis formation in vivo. J Clin Invest 1988; 81:1012-1019.
5. Honn KV. Tang DG. Chen YQ: Platelets and cancer metastasis: More than an epiphenomc-non. Semin Thromb Hemost 1992:18:392-415.
6. Honn KV. Cicone B. Skoff A: Prostacyclin: A potent anti-metastatic agent. Science 1981; 212:1270-1272.
7. Constantini V. Zacharski LR. Moritz TE. Edwards RL: The platelet count in carcinoma of the lung and colon. Thromb I laemost 1990:64: 501-505.
8. I lcath CW, Thun MJ. Greenberg ER. Levin B, Marnett LJ: Nonsteroidal antiinflammatory drugs and human cancer. Report of an interdisciplinary research workshop. Cancer 1994:74: 2885-2888.
9. Trousseau A: Phlegmasia alba dolens. Clinique Medicale de L'Hötcl de Paris. London, The New Sydenham Society, 1865. vol 3, pp. 654-656.
10. Dvorak H: Thrombosis and cancer. Hum Pathol 1987:18:275-284.
11. Falanga A. Gordon SG: Isolation and characterization of cancer procoagulant: A cystein proteinase from malignant tissue. Biochemistry 1985;24:5558-5567.
12. Tohogo A. Tanaka N. Ogawa H: Platelet-aggregating activities of metastasizing tumor cells. III. Platelet aggregation as resulting from thrombin generation by tumor cells. Invasion Mctast 1985;5:96-105.
13. Wood S: Pathogenesis of metastasis formation observed in vivo in the rabbit ear chamber. Arch Pathol 1958;66:550-568.
14. Esumi N. Fan D. Fidler 1J: Inhibition of murine melanoma experimental metastasis by recombinant desulfatohirudin. a highly specific thrombin inhibitor. Cancer Res 1991:51:4549-4556.
15. Tuszynski GP, Gasic TB. Gasic GJ: Isolation and characterization of antistasin: An inhibitor of metastasis and coagulation. J Biol Chem 1987;262:9718-9723.
16. Aisner J, Goutsou M. Maurer LH. Cooper R, Chahinian P. Carey R. Skarin A. Slawson R. Perry MC, Green MR: Intensive combination chemotherapy, concurrent chest irradiation, and warfarin for the treatment of limited-dis-case small-cell lung cancer: A cancer and leukemia group B pilot study. J Clin Oncol 1992:10: 1230-1236.
17. Tuszynski GP. Rothman V. Murphy A, Siegler K. Smith L. Smith S, Karczewski J. Knudscn KA: Thrombospondin promotes ccll-infstra-tum adhesion. Science 1987;236:1570-1573.
18. Tuszynski GP, Gasic TB, Rothman VL. Knudscn, KA. Gasic GJ: Thrombospondin, a potentiator of tumor cell metastasis. Cancer Res 1987:47:4130-4133.
19. Nathan FE, Hernandez E, Dunlon CJ. Treat J. Switalska HI. Joseph RR, Tuszynski GP: Plasma thrombospondin levels in patients with gynecologic malignancies. Cancer 2858.
20. Tang DG, Onoda JM, Steinert BW, Grossi IM, Nelson KK, Umbarger L, Diglio CA. Taylor JD. Honn KV: Phenotypic properties of cultured tumor cells: Integrin alpha lib beta 3 expression, tumor-cell-induced platelet aggregation. and tumor-cell adhesion to endothelium as important parameters of experimental metastasis. Int J Cancer 1993:54:338-347.
21. Crissman JD, Hatfield J, Schaldenbrand M. Sloane BF. Honn KV: Arrest and extravasation of B16 amelanotic melanoma in murine lungs: A light and electron microscopic study. Lab Invest 1985;53:470-478.
22. Tuszynski GP. Rothman VL, Murphy A, Siegler K, Knudscn KA: Thrombospondin promotes platelet aggregation. Blood 1988:72: 109-115.
23. Kehrel B. Balleisen L, Kokott R. Mesters R. Stenzinger W, Clemetson KJ. Van de Loo J: Deficiency of intact thrombospondin and membrane glycoprotein la in platelets with defective collagen-induced aggregation and spontaneous loss of disorder. Blood 1988:71:1074- 1078.
24. Katagiri Y. Hayashi Y, Baba I, Suzuki H. Tanoue K. Yamazaki H: Characterization of platelet aggregation induced by the human melanoma cell line HMV-1: Roles of heparin, plasma adhesive proteins, and tumor cell membrane proteins. Cancer Res 1991:51:1286- 1293.
25. Clezardin P. Serre C-M. Trzeciak M-C. Drouin J. Delmas PD: Thrombospondin binds to the surface of human osteosarcoma cells and mediates platclct-osteosarcoma cell interaction. Cancer Res 1991;51:2621-2627.
26. Incardona F, Lewalle JM, Morandi V, Lambert S, Legrand Y. Foidart JM. Legrand C: Thrombospondin modulates human breast adenocarcinoma cell adhesion to human vascular endothelial cells. Cancer Res 1995;55:166-173.
27. Tuszynski GP. Rothman VL, Deutch AH. Hamilton BK. Eyal J: Biological activities of peptides and peptide analogues derived from common sequences present in thrombospon-din. properdin, and malarial proteins. J Cell Biol 1992;116:209-217.
28. Liotta L: Tumor invasion and mctastases-role of the extracellular matrix. Cancer Res 1991; 46:1-7.
29. Barsky SH, Rao CN, Williams JE. Liotta LA: Laminin molecular domains which alter metastasis in a murine model. J Clin Invest 1984:74: 843-848.
30. Iwamoto Y. Robey FA. Graf J. Sasaki M, Kleinman HK. Yamada Y, Martin GR: Y1GSR. a synthetic laminin pentapcptidc. inhibits experimental metastasis formation. Science 1987:238:1132-1134.
31. Pierschbacher MD, Ruoslahti E: Cell attachment activity of fibroncctin can be duplicated by small synthetic fragments of the molecule. Nature 1994;309:30-33.
32. Humphries MJ, Olden K. Yamada KM: A synthetic peptide from fibronectin inhibits experimental metastasis of murine melanoma cells. Science 1986:233:467-470.
33. Humphries MJ, Yamada KM. Olden K: Investigation of the biological effects of anti-cell adhesive synthetic peptides that inhibit experimental métastasés of B16-F10 murine melanoma cells. J Clin Invest 1988;81:782-790.
34. Soszka T, Knudsen KA. Beviglia L. Rossi C, Poggi A. Niewiarowski S: Inhibition of murine melar.oma cell-matrix adhesion and experimental metastasis by albolabrin, an RGD-con-taining peptide isolated from the venom of Tri-meresurits albolabris. Exp Cell Res 1991 96: 6-12.
35. Laurent TC. Fraser JR: Myaluronan. FASEB J 1992;5:2397-2404.
36. Sherman L, Sleeman J. Herrlich P. Ponta H: Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. CurrOpin Cell Biol 1994;6:726-733.
37. Rooney P. Kumar S, Ponting J. Wang M: The role of hyaluronan in tumour neovascularization. Int J Cancer 1995;60:632-636.
38. Tuszynski GP. Rothman VL, Papale M. Hamilton BK. Eyal J: Identification and characterization of a tumor cell receptor for CSVTCG. a thrombospondin adhesive domain. J Cell Biol 1993:120:513-521.
39. Amoletti JP. Albo D. Jhala N, Granick MS. Solomon MP. Atkinson B. Rothman VL. Tuszynski GP: Computer-assisted image analysis of tumor sections for a new thrombospondin receptor. Am J Surg 1994:168:433-436.
40. Tuszynski GP. Nicosia RF: Localization of thrombospondin and itscysteine-serine-valine-threonine-cystcinc-glycinc-specific receptor in human breast carcinoma. Lab Invest 1994;70: 228-233.
41. Terranova VP, Liotta LA. Russo RG. Martin GR: Role of laminin in the attachment and metastasis of murine tumor cells. Cancer Res 1982:42:2265-2269.
42. Mecham RP. Receptors for laminin on mammalian cells. FASEB J 1991:5:2538-2546.
43. Demetcr LM. Stoler MH. Sobcl ME, Broker TR, Chow LT: Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillo-ma-virus-associated cervical neoplasms. Cancer Res 1992:52:1561-1567.
44. Gasparini G, Barbareschi M. Boracchi P. Bevi-lacqua P, Verdcrio P. Palma PD, 67-kDa Laminin-receptor expression adds prognostic information to intra-tumoral microvessel density in node-negative breast cancer. Int J Cancer 1995:60:604-610.
45. Telan MJ. Eisenbarth GS, Haynes BF: Human erythrocyte antigens. Regulation of expression of a novel erythrocyte surface antigen by the inhibitor l.uthcrcn In(Lu) gene. J Clin Invest 1983:71:1878-1886.
46. Telan MJ, Palker TJ, Haynes BF: Human erythrocyte antigens. II. The In(Lu) gene regulates expression of an antigen on an 80-kilodal-ton protein of human erythrocytes. Blood 1984:64:599-606.
47. Naujokas MF. Morin M. Anderson MS, Peterson M, Miller J: The chondroitin sulfate form of invariant chain can enhance stimulation of T cell responses through interaction with CD44. Cell 1993:74:257-268.
48. Belitsos PC. Hildreth JE, August JT: Homotyp-ic cell aggregation induced by anti-CD44 (Pgp-1) monoclonal antibodies and related to CD44 (Pgp-1) expression. J Immunol 1990:144: 1661-1670.
49. Jalkancn S, Bargatze RF, Herron LR. Butcher EC: A lymphoid cell surface glycoprotein involved in endothelial cell recognition and lymphocyte homing in man. Eur J Immunol 1986: 16:1195-1202.
50. Aruffo A. Stamcnkovic I, Melnick M, Underhill CB. Seed B: CD44 is the principal cell surface receptor for hyaluronate. Cell 1990:61: 1303-1313.
51. Heider KH. van den Berg F, Hofmann M. Ponta H. Herrlick P. Pals ST: A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps. J Cell Biol 1993:120:227-233.
52. Matsamura Y, Tarin D: Significance of CD44 gene products for cancer diagnosis and disease evaluation. Lancet 1992:340:1053-1058.
53. Tanabe K. Ellis LM, Saya H: Expression of CD44R1 adhesion molecule in colon carcinoma and metastasis. Lancet 1993:341:725-726.
54. Joensuu H. Klemi PJ. Toikkanen S. Jalkanen S: Glycoprotein CD44 expression and its association with survival in breast cancer. Am J Pathol 1993;143:867-874.
55. Jalkancn S, Joensuu H. Söderström KO, Klemi PJ: Lymphocyc homing and clinical behavior of non-Hodgkin lymphoma. J Clin Invest 1991; 87:1835-1840.
56. Li H. Hamou M.Tibolct N. Jaufeerally R. Hofmann M,: Variant CD44 adhesion molecules are expressed in human brain mctastases but not in glioblastomas. Cancer Res 1993;53:5345-5349.
57. Cannistra SA, Kansas GS, Niloff J. DcFranzo B. Kim Y. Ottensmcier C: Binding of ovarian cancer cells to peritoneal mcsothelium in vitro is partly mediated by CD44H. Cancer Res 1993:53:3830-3838.
58. Penno MB. August JT, Baylin SB, Mabry M, Linnoila RI, Lee VS: Expression of CD44 in human lung tumors. Cancer Res 1994:54: 1381-1387.
59. Guo Y-J, Liu G. WangX: Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54:422-426.
60. Birch M, Mitchell S. Hart Isolation and characterization of human melanoma cell variants expression high and low levels of CD44. Cancer Res 1991:51:6660-6667.
61. Hofman M. Rudy W, Zoller M. Tolf C, Ponta H. Herrlich P, Gunthert U: CD44 splice variants confer metastatic behavior in rats: Homologous sequences arc expressed in human tumor cell lines. Cancer Res 1991:51:5292-5297.
62. Nagasaka S. Tanabe KK. Bruner JM: Alternative RNA splicing of the hyaluronic aid receptor, CD44, in normal human brain and brain tumors. J Neurosurg 1995:82:858-863.
63. Wielenga VJM, Heider, K-H, Offerhaus GJA, Adolf GR, van den Berg, FM, Ponta, H, Herrlich P, Pals ST: Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. Cancer Res 1993:53: 4754-4756.
64. Sherman L, Slccman J. Herrlich P. Hyaluronate receptors: Key players in growth, differentiation, migration and tumor progression. CurrOpin Cell Biol 1994:6:726-733.
65. Culty M. Nguyen HA, Underhill CB: The hya-luronan receptor (CD44) participates in the uptake and degradation of hyaluronan. J Cell Biol 1992:116:1055-1062.
66. Bartolazzi A. Peach R. Aruffo A. Stamenkovic I: Interaction between CD44 and hyaluronate is directly implicated in the regulation of tumor development. J Exp Med 1994: 180:53-66.
67. Thomas L. Byers HR. Vink J, Stamenkovic I: CD44H regulates tumor cell migration on hyal-uronatc-coated infstrate. J Cell Biol 1992:118: 971-977.
68. Gunther U. Hofmann M. Rudy W, Reber S. Zoller M, Haubmann I. Matzku S. Wenzel A. Ponta H, Herrlich: A new variant of glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell 1991;65:13-24.
69. Tanabe KK. Stamenkovic I. Cutler M, Takaha-shi K: Restoration of CD44H expression in colon carcinomas reduces tumorigenicity. Ann Surg 1995:222:493-503.
70. Fox SB. Fawcett J. Jackson DG, Collins I. Gatter KC, Harris AL. Gearing A, Simmons DL: Normal human tissues, in addition to some tumors, express multiple different CD44 isoforms. Cancer Res 1994:54:4539-4546.
71. Bosman FT: Integrins: Cell adhesives and modulators of cell function. Histochcm J 1993:25: 469-477.
72. Hynes RO: Integrins: Versatility, modulation, and signalling in cell adhesion. Cell 1992:69: 11-25.
73. Hynes RO: Integrins: A family of cell surface receptors. Cell 1987:48:549-554.
74. Chen WT. Hasegawa T. Hascgawa C. Wein-stock C, Yantada KM: Development of cell surface lineage complexes in cultivated fibroblasts. J Cell Biol 1985; 100:1103-1114.
75. Damsky CM, Knudsen KA. Bradley D. Buck CA, Horwitz A: Distribution of the CSAT ccll-matrix antigen on myogenic and fibroblastic cells in culture. J Cell Biol 1985:100:1528-1539.
76. Burridge K, Fath K. Kelly T, Nuckolls G, Turner C: Focal adhesions: Transmcmbranc junctions between the extracellular matrix and the cytoskeleton. Annu Rev Cell Biol 1988:4:487- 525.
77. Dejfnna E. Colclla S, Conforti G, Abbadini M, Gaboli M. Marchisio PC: Fibronectin and vitronectin regulate the organization of their respective Arg-Glv-Asp adhesion receptors in cultured human endothelial cells. J Cell Biol 1988;107:1215-1223.
78. vp; on human melanoma cells. Cancer Metastasis Rev 1991; 10:3- 10.
79. Brooks PC, Clark RAF, Chcresh DA: Requirement of vascular integrin a, S i for angiogenesis. Science 1994;264:569-571.
80. Brooks PC, Montgomery AMP. Rosenfeld M. Reisfcld RA. Integrin vlSi antagonists promote tumor regression by inducing apoptosis of angiogenic blood vessels. Cell 1994:79:1157-1164.
81. vps integrins in avian neural cres: adhesion and migration on vitronectin. Development 1994;120:2687-2702.
82. Albelda SM. Mette SM, Elder DE. Stewart R. Damjanovich L, Herlyn M. Buck CA: Integrin distribution in malignant melanoma: association of the pi infunit with tumor progression. Cancer Res 1991:50:6757-6764.
83. Cheresh DA, Spiro RC: Biosynthetic and functional properties of an Arg-Glv-Asp directed receptor involved in human melanoma cell attachment to vitronectin, fibrinogen and von Willebrand factor. J Biol Chcm 1987:262: 17703-17711.
84. Cheresh DA: Human endothelial cells synthesize and express an Arg-Gly-Asp directed receptor involved in attachment to fibrinogen and von Willebrand factor. Proc Natl Acad Sci USA 1987:84:6471-6475.
85. Tuszynski GP. Karczcwski J. Smith L. Murphy A. Rothman VL, Knudsen KA: The GPI1B-IIla-like complex may function as a human melanoma cell adhesion receptor for thrombo-spondin. ExpCell Res 1989:182:473-481.
86. Reinholt FP. Hultcnby K, Oldberg A. Hcine-gard D: Osteopontin - a possible anchor of osteoclasts to bone. Proc Natl Acad Sci USA 1990;87:4473-4475.
87. vpj in promoting cellular attachment and spreading on fibronectin. J Cell Biol 1991:111:2795-2800.
88. Kramer RH. Cheng Y-F, Clyman R: Fluman microvascular endothelial cells use Pi and pi integrin receptor complexes to attach to lamin-in. J Cell Biol 1990:111:1233-1243.
89. Fclding-Haberman B. Mueller BM, Romcrdahl CA. Cheresh DA: Involvement of integrin av gene expression in human melanoma tumori-gcnicity. J Clin Invest 1992:89:2018-2022.
90. vp.? to adhere to lymph node vitronectin. J Clin Invest 1992:90:1406-1413.
91. vp3 integrin in human melanoma cell invasion. Proc Natl Acad Sci USA 1992;89:1557-1561.
92. Gehlson KR. Argraves WS. Pierschbacher MD, Ruoslahti E: Inhibition of in vitro tumor invasion by Arg-Gly-Asp-containing peptides. J Cell Biol 1988:106:925-930.
93. Nip J. Rabbani SA. Shibata HR, Brodt P: Coordinated expression of the vitronectin receptor and the urokinase-type plasminogen activator receptor in metastastic melanoma cells. J Clin Invest 1995:95:2096-2103.
94. Montgomery AMP. Reisfeld RA, Cheresh DA: Integrin cxvpj rescues melanoma cells from apoptosis in three-dimensional dermal collagen. Proc Natl Acad Sci USA 1994:91: 8856-8860.
95. Folkntan J: The role of angiogensis in tumor growth. Semin Cancer Biol 1992;3:65-71.
96. vPj blocks human breast cancer growth and an-giogenesis in human skin. J Clin Invest 1995; 96:1815-1822